 |
|
Borderline and Schizotypal Personality Disorders Treated With Low-Dose Thiothixene vs Placebo
Solomon C. Goldberg, PhD;
S. Charles Schulz, MD;
Patricia M. Schulz, MSW;
Robert J. Resnick, PhD;
Robert M. Hamer, PhD;
Robert O. Friedel, MD
Arch Gen Psychiatry. 1986;43(7):680-686.
Abstract
| |
• Fifty outpatients with borderline and/or schizotypal personality disorder were randomly allocated to thiothixene (Navane) or placebo treatment that was continued for 12 weeks. The mean daily dosage of thiothixene hydrochloride in the final week of the study was 8.7 mg, a lower dosage than is used in outpatient schizophrenics. Significant drug-placebo differences were found, regardless of diagnosis, on "illusions," "ideas of reference," "psychoticism," "obsessivecompulsive symptoms," and "phobic anxiety," but not on "depression." Thiothixene seems to have more than an antipsychotic effect. Since response to treatment studies are a means for reformulating diagnostic concepts, we suggest a subdiagnosis defined by those symptoms that are drug-responsive, some of which are not included in current diagnostic criteria. Patients with borderline and schizotypal disorder without the foregoing symptoms probably would not profit from thiothixene and might needlessly be placed at risk for adverse drug effects.
Author Affiliations
From the Department of Psychiatry, Medical College of Virginia/Virginia Commonwealth University, Richmond. Dr Schulz is now at the Western Psychiatric Institute and Clinic, Pittsburgh; Dr Friedel is now at Charter Westbrook Hospital, Richmond.
Footnotes
Accepted for publication Aug 20, 1985.
Reprint requests to Department of Psychiatry, Medical College of Virginia/Virginia Commonwealth University, PO Box 710, Richmond, VA 23298 (Dr Goldberg).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
Schulz et al.
Br. J. Psychiatry 2008;193:485-492.
ABSTRACT
| FULL TEXT
Drug treatment for personality disorders
Tyrer and Bateman
Adv. Psychiatr. Treat. 2004;10:389-398.
ABSTRACT
| FULL TEXT
Efficacy of Phenelzine and Haloperidol in Borderline Personality Disorder
Soloff et al.
Arch Gen Psychiatry 1993;50:377-385.
ABSTRACT
Impact of Treatment Accessibility on Clinical Course of Parasuicidal Patients-Reply
Linehan and Heard
Arch Gen Psychiatry 1993;50:157-158.
ABSTRACT
Increased Morbid Risk for Schizophrenia Related Disorders in Relatives of Schizotypal Personality Disordered Patients
Siever et al.
Arch Gen Psychiatry 1990;47:634-640.
ABSTRACT
Pharmacotherapy of Borderline Personality Disorder: Alprazolam, Carbamazepine, Trifluoperazine, and Tranylcypromine
Cowdry and Gardner
Arch Gen Psychiatry 1988;45:111-119.
ABSTRACT
Pharmacotherapy for Patients With Borderline Personality Disorder
Goldberg
Arch Gen Psychiatry 1988;45:195-196.
ABSTRACT
Pharmacotherapy for Patients With Borderline Personality Disorder
Gunderson
Arch Gen Psychiatry 1986;43:698-700.
ABSTRACT
|
